We are live on ! Find out more
IGC icon

IGC Pharma

25 hedge funds and large institutions have $5.08M invested in IGC Pharma in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

553% more capital inflows, than outflows

Capital inflows: $2.09M | Capital outflows: $320K

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

4% more funds holding

Funds holding: 24 → 25 (+1)

2.51% more ownership

Funds ownership: 5.1% → 7.62% (+2.5%)

22% less call options, than puts

Call options by funds: $377K | Put options by funds: $485K

Holders
25
Holders Change
+1
Holders Change %
+4.17%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
5
Closed
4
Calls
$377​K
Puts
$485​K
Net Calls
-⁠$108​K
Net Calls Change
-⁠$126​K

IGC Hedge Fund Activity: Q4 2020 in Review

25 of the 5,680 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2020, worth a combined $5.08M — up 132% from $2.18M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IGC positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $1.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $115K sold.

  • 25 institutional investors held IGC Pharma (IGC) as of Q4 2020, up from 24 in Q3 2020.
  • Funds reported $5.08M of IGC Pharma stock for Q4 2020, up 132% quarter-over-quarter.
  • 5 funds opened new IGC Pharma positions in Q4 2020 and 4 closed out, a net change of +1 holder.
  • The largest IGC Pharma buyer in Q4 2020 was BlackRock, an estimated $1.3M added.
  • The largest IGC Pharma seller in Q4 2020 was Renaissance Technologies, an estimated $115K sold.

Based on aggregated 13F filings for Q4 2020.